Bafna Pharmaceuticals Limited (BAFNAPH) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.030x

Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) has a cash flow conversion efficiency ratio of 0.030x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs24.82 Million ≈ $268.44K USD) by net assets (Rs823.66 Million ≈ $8.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Bafna Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Bafna Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bafna Pharmaceuticals Limited (BAFNAPH) total liabilities for a breakdown of total debt and financial obligations.

Bafna Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bafna Pharmaceuticals Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Podium Minerals Ltd AU:POD	-0.007x
DJ Mediaprint & Logistics Limited NSE:DJML	-0.318x
CervoMed Inc. NASDAQ:CRVO	-0.249x
FACB Industries Incorporated KLSE:2984	-0.007x
MERUS POWER OYJ EO 1 F:99H	N/A
Arizona Lithium Ltd AU:AZL	-0.047x
WINSON Machinery Co Ltd TWO:4538	0.001x
Tron Inc. NASDAQ:TRON	-0.004x

Annual Cash Flow Conversion Efficiency for Bafna Pharmaceuticals Limited (2005–2025)

The table below shows the annual cash flow conversion efficiency of Bafna Pharmaceuticals Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see BAFNAPH market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	Rs848.07 Million ≈ $9.17 Million	Rs195.29 Million ≈ $2.11 Million	0.230x	+96.27%
2024-03-31	Rs808.39 Million ≈ $8.74 Million	Rs94.85 Million ≈ $1.03 Million	0.117x	+74.02%
2023-03-31	Rs734.55 Million ≈ $7.94 Million	Rs49.52 Million ≈ $535.59K	0.067x	-57.06%
2022-03-31	Rs619.64 Million ≈ $6.70 Million	Rs97.28 Million ≈ $1.05 Million	0.157x	+165.49%
2021-03-31	Rs567.71 Million ≈ $6.14 Million	Rs-136.09 Million ≈ $-1.47 Million	-0.240x	+64.19%
2020-03-31	Rs511.95 Million ≈ $5.54 Million	Rs-342.68 Million ≈ $-3.71 Million	-0.669x	-606.06%
2019-03-31	Rs188.52 Million ≈ $2.04 Million	Rs-17.87 Million ≈ $-193.28K	-0.095x	+49.95%
2018-03-31	Rs372.02 Million ≈ $4.02 Million	Rs-70.47 Million ≈ $-762.14K	-0.189x	-742.20%
2017-03-31	Rs421.12 Million ≈ $4.55 Million	Rs-9.47 Million ≈ $-102.44K	-0.022x	-242.15%
2016-03-31	Rs575.71 Million ≈ $6.23 Million	Rs9.11 Million ≈ $98.52K	0.016x	-89.21%
2015-03-31	Rs727.13 Million ≈ $7.86 Million	Rs106.65 Million ≈ $1.15 Million	0.147x	+536.93%
2014-03-31	Rs697.48 Million ≈ $7.54 Million	Rs16.06 Million ≈ $173.70K	0.023x	-95.71%
2013-03-31	Rs683.04 Million ≈ $7.39 Million	Rs366.32 Million ≈ $3.96 Million	0.536x	+460.94%
2012-03-31	Rs646.17 Million ≈ $6.99 Million	Rs-96.01 Million ≈ $-1.04 Million	-0.149x	-26.74%
2011-03-31	Rs541.89 Million ≈ $5.86 Million	Rs-63.53 Million ≈ $-687.07K	-0.117x	-708.49%
2010-03-31	Rs410.05 Million ≈ $4.43 Million	Rs-5.95 Million ≈ $-64.31K	-0.015x	+96.00%
2009-03-31	Rs385.23 Million ≈ $4.17 Million	Rs-139.82 Million ≈ $-1.51 Million	-0.363x	-105.51%
2008-03-31	Rs118.55 Million ≈ $1.28 Million	Rs-20.94 Million ≈ $-226.43K	-0.177x	-115.97%
2007-03-31	Rs91.39 Million ≈ $988.34K	Rs101.06 Million ≈ $1.09 Million	1.106x	+1151.53%
2006-03-31	Rs56.78 Million ≈ $614.05K	Rs-5.97 Million ≈ $-64.57K	-0.105x	+83.71%
2005-03-31	Rs42.55 Million ≈ $460.13K	Rs-27.46 Million ≈ $-297.02K	-0.646x	--

About Bafna Pharmaceuticals Limited

NSE:BAFNAPH India Drug Manufacturers - Specialty & Generic

Market Cap

$34.28 Million

Rs3.17 Billion INR

Market Cap Rank

#23257 Global

#1289 in India

Share Price

Rs134.00

Change (1 day)

+1.64%

52-Week Range

Rs72.00 - Rs192.44

All Time High

Rs507.50